Adult hematopoietic stem cell transplantation in eastern Taiwan

Initial results at Tzu Chi Hospital from 2002 to 2005

Sung Chao Chu, Chi Cheng Li, Tso Fu Wang, Chao Yuan Yao, Ruey Ho Kao

研究成果: 雜誌貢獻文章

摘要

Objective: Hematopoietic stem cell transplantation (HSCT) has proved to be an important curative therapy for various hematological disorders. Here we present the first report of adult HSCT at one institution in eastern Taiwan. Patients and Methods: Thirteen patients, 7 men and 6 women, underwent HSCT between July 2002 and March 2005. Their median age was 34 years (range: 22-51). Five patients had acute myeloid leukemia, 2 had acute lymphoblastic leukemia, 2 had chronic myeloid leukemia, 2 had severe aplastic anemia, one had non-Hodgkin's lymphoma and one had Hodgkin's disease. Eleven patients received HLA-identical allogeneic transplantations, including two unrelated donor transplantations. Two patients received autologous transplantations. The conditioning regimens were total body irradiation plus busulfan or busulfan plus cyclophophamide for allogeneic transplantation, and BEAM for autotransplantation. The prevention of graft versus host disease (GVHD) employed standard cyclosporine and methotrexate. Results: The median numbers of CD34 positive cells obtained were 1.9 ÷ 106/kg of patient body weight from bone marrow harvest and 6.5 × 106/kg from peripheral blood stem cell collection. The overall engraftment rate was 100%. The median times to neutrophil and platelet engraftments were 11.4 and 11.2 days, respectively. The one-year event-free and one-year overall survivals were both 90%. Acute GVHD of grade II-IV was seen in 8 out of 11 patients (72.7%) of whom 2 had grade III-IV disease (18.2%). Chronic GVHD developed in 6 out of 10 evaluable patients (60%) with 3 in limited stages and 3 in extensive stages. Eleven patients were alive and free of disease at 124 to 1117 days, with a median survival of 649 days after transplantation. One patient who underwent unrelated transplantation died of CMV pneumonitis on day 67. One patient died of disease relapse on day 485. The median Karnofsky Performance Score of surviving patients was 90%. Conclusion: The study demonstrates that HSCT in our hospital has achieved promising results and patients can obtain long-term disease-free survival and good social function.
原文英語
期刊Tzu Chi Medical Journal
18
發行號2
出版狀態已發佈 - 四月 1 2006
對外發佈Yes

指紋

Adult Stem Cells
Hematopoietic Stem Cell Transplantation
Taiwan
Graft vs Host Disease
Busulfan
Autologous Transplantation
Transplantation
Homologous Transplantation
Unrelated Donors
Survival
Aplastic Anemia
Whole-Body Irradiation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hodgkin Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Methotrexate
Non-Hodgkin's Lymphoma
Cyclosporine
Disease-Free Survival

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Adult hematopoietic stem cell transplantation in eastern Taiwan : Initial results at Tzu Chi Hospital from 2002 to 2005. / Chu, Sung Chao; Li, Chi Cheng; Wang, Tso Fu; Yao, Chao Yuan; Kao, Ruey Ho.

於: Tzu Chi Medical Journal, 卷 18, 編號 2, 01.04.2006.

研究成果: 雜誌貢獻文章

@article{998438513b594fe4abd22d3d3ab970c0,
title = "Adult hematopoietic stem cell transplantation in eastern Taiwan: Initial results at Tzu Chi Hospital from 2002 to 2005",
abstract = "Objective: Hematopoietic stem cell transplantation (HSCT) has proved to be an important curative therapy for various hematological disorders. Here we present the first report of adult HSCT at one institution in eastern Taiwan. Patients and Methods: Thirteen patients, 7 men and 6 women, underwent HSCT between July 2002 and March 2005. Their median age was 34 years (range: 22-51). Five patients had acute myeloid leukemia, 2 had acute lymphoblastic leukemia, 2 had chronic myeloid leukemia, 2 had severe aplastic anemia, one had non-Hodgkin's lymphoma and one had Hodgkin's disease. Eleven patients received HLA-identical allogeneic transplantations, including two unrelated donor transplantations. Two patients received autologous transplantations. The conditioning regimens were total body irradiation plus busulfan or busulfan plus cyclophophamide for allogeneic transplantation, and BEAM for autotransplantation. The prevention of graft versus host disease (GVHD) employed standard cyclosporine and methotrexate. Results: The median numbers of CD34 positive cells obtained were 1.9 ÷ 106/kg of patient body weight from bone marrow harvest and 6.5 × 106/kg from peripheral blood stem cell collection. The overall engraftment rate was 100{\%}. The median times to neutrophil and platelet engraftments were 11.4 and 11.2 days, respectively. The one-year event-free and one-year overall survivals were both 90{\%}. Acute GVHD of grade II-IV was seen in 8 out of 11 patients (72.7{\%}) of whom 2 had grade III-IV disease (18.2{\%}). Chronic GVHD developed in 6 out of 10 evaluable patients (60{\%}) with 3 in limited stages and 3 in extensive stages. Eleven patients were alive and free of disease at 124 to 1117 days, with a median survival of 649 days after transplantation. One patient who underwent unrelated transplantation died of CMV pneumonitis on day 67. One patient died of disease relapse on day 485. The median Karnofsky Performance Score of surviving patients was 90{\%}. Conclusion: The study demonstrates that HSCT in our hospital has achieved promising results and patients can obtain long-term disease-free survival and good social function.",
keywords = "Eastern Taiwan, Graft versus host disease, Hematopoietic stem cell transplantation, Survival",
author = "Chu, {Sung Chao} and Li, {Chi Cheng} and Wang, {Tso Fu} and Yao, {Chao Yuan} and Kao, {Ruey Ho}",
year = "2006",
month = "4",
day = "1",
language = "English",
volume = "18",
journal = "Tzu Chi Medical Journal",
issn = "1016-3190",
publisher = "財團法人中華民國佛教慈濟慈善事業基金會",
number = "2",

}

TY - JOUR

T1 - Adult hematopoietic stem cell transplantation in eastern Taiwan

T2 - Initial results at Tzu Chi Hospital from 2002 to 2005

AU - Chu, Sung Chao

AU - Li, Chi Cheng

AU - Wang, Tso Fu

AU - Yao, Chao Yuan

AU - Kao, Ruey Ho

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Objective: Hematopoietic stem cell transplantation (HSCT) has proved to be an important curative therapy for various hematological disorders. Here we present the first report of adult HSCT at one institution in eastern Taiwan. Patients and Methods: Thirteen patients, 7 men and 6 women, underwent HSCT between July 2002 and March 2005. Their median age was 34 years (range: 22-51). Five patients had acute myeloid leukemia, 2 had acute lymphoblastic leukemia, 2 had chronic myeloid leukemia, 2 had severe aplastic anemia, one had non-Hodgkin's lymphoma and one had Hodgkin's disease. Eleven patients received HLA-identical allogeneic transplantations, including two unrelated donor transplantations. Two patients received autologous transplantations. The conditioning regimens were total body irradiation plus busulfan or busulfan plus cyclophophamide for allogeneic transplantation, and BEAM for autotransplantation. The prevention of graft versus host disease (GVHD) employed standard cyclosporine and methotrexate. Results: The median numbers of CD34 positive cells obtained were 1.9 ÷ 106/kg of patient body weight from bone marrow harvest and 6.5 × 106/kg from peripheral blood stem cell collection. The overall engraftment rate was 100%. The median times to neutrophil and platelet engraftments were 11.4 and 11.2 days, respectively. The one-year event-free and one-year overall survivals were both 90%. Acute GVHD of grade II-IV was seen in 8 out of 11 patients (72.7%) of whom 2 had grade III-IV disease (18.2%). Chronic GVHD developed in 6 out of 10 evaluable patients (60%) with 3 in limited stages and 3 in extensive stages. Eleven patients were alive and free of disease at 124 to 1117 days, with a median survival of 649 days after transplantation. One patient who underwent unrelated transplantation died of CMV pneumonitis on day 67. One patient died of disease relapse on day 485. The median Karnofsky Performance Score of surviving patients was 90%. Conclusion: The study demonstrates that HSCT in our hospital has achieved promising results and patients can obtain long-term disease-free survival and good social function.

AB - Objective: Hematopoietic stem cell transplantation (HSCT) has proved to be an important curative therapy for various hematological disorders. Here we present the first report of adult HSCT at one institution in eastern Taiwan. Patients and Methods: Thirteen patients, 7 men and 6 women, underwent HSCT between July 2002 and March 2005. Their median age was 34 years (range: 22-51). Five patients had acute myeloid leukemia, 2 had acute lymphoblastic leukemia, 2 had chronic myeloid leukemia, 2 had severe aplastic anemia, one had non-Hodgkin's lymphoma and one had Hodgkin's disease. Eleven patients received HLA-identical allogeneic transplantations, including two unrelated donor transplantations. Two patients received autologous transplantations. The conditioning regimens were total body irradiation plus busulfan or busulfan plus cyclophophamide for allogeneic transplantation, and BEAM for autotransplantation. The prevention of graft versus host disease (GVHD) employed standard cyclosporine and methotrexate. Results: The median numbers of CD34 positive cells obtained were 1.9 ÷ 106/kg of patient body weight from bone marrow harvest and 6.5 × 106/kg from peripheral blood stem cell collection. The overall engraftment rate was 100%. The median times to neutrophil and platelet engraftments were 11.4 and 11.2 days, respectively. The one-year event-free and one-year overall survivals were both 90%. Acute GVHD of grade II-IV was seen in 8 out of 11 patients (72.7%) of whom 2 had grade III-IV disease (18.2%). Chronic GVHD developed in 6 out of 10 evaluable patients (60%) with 3 in limited stages and 3 in extensive stages. Eleven patients were alive and free of disease at 124 to 1117 days, with a median survival of 649 days after transplantation. One patient who underwent unrelated transplantation died of CMV pneumonitis on day 67. One patient died of disease relapse on day 485. The median Karnofsky Performance Score of surviving patients was 90%. Conclusion: The study demonstrates that HSCT in our hospital has achieved promising results and patients can obtain long-term disease-free survival and good social function.

KW - Eastern Taiwan

KW - Graft versus host disease

KW - Hematopoietic stem cell transplantation

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33745089914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745089914&partnerID=8YFLogxK

M3 - Article

VL - 18

JO - Tzu Chi Medical Journal

JF - Tzu Chi Medical Journal

SN - 1016-3190

IS - 2

ER -